308 related articles for article (PubMed ID: 37117649)
1. Reshaping the tumour immune microenvironment in solid tumours via tumour cell and immune cell DNA methylation: from mechanisms to therapeutics.
Zhong F; Lin Y; Zhao L; Yang C; Ye Y; Shen Z
Br J Cancer; 2023 Jul; 129(1):24-37. PubMed ID: 37117649
[TBL] [Abstract][Full Text] [Related]
2. The interaction between DNA methylation and tumor immune microenvironment: from the laboratory to clinical applications.
Zhu D; Zeng S; Su C; Li J; Xuan Y; Lin Y; Xu E; Fan Q
Clin Epigenetics; 2024 Feb; 16(1):24. PubMed ID: 38331927
[TBL] [Abstract][Full Text] [Related]
3. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
Liu M; Zhou J; Chen Z; Cheng AS
J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
[TBL] [Abstract][Full Text] [Related]
4. DNA methylation in the tumor microenvironment.
Zhang MW; Fujiwara K; Che X; Zheng S; Zheng L
J Zhejiang Univ Sci B; 2017 May; 18(5):365-372. PubMed ID: 28471108
[TBL] [Abstract][Full Text] [Related]
5. DNA methylation regulator-mediated modification patterns and tumor microenvironment characterization in glioma.
Luo H; Ye M; Hu Y; Wu M; Cheng M; Zhu X; Huang K
Aging (Albany NY); 2022 Sep; 14(19):7824-7850. PubMed ID: 36152044
[TBL] [Abstract][Full Text] [Related]
6. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
7. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
Loo Yau H; Ettayebi I; De Carvalho DD
Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic targeting of DNA methylation alterations in cancer.
Lee AV; Nestler KA; Chiappinelli KB
Pharmacol Ther; 2024 Jun; 258():108640. PubMed ID: 38570075
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting DNA methylation and RNA editing upregulates immunogenic RNA to transform the tumor microenvironment and prolong survival in ovarian cancer.
Gomez S; Cox OL; Walker RR; Rentia U; Hadley M; Arthofer E; Diab N; Grundy EE; Kanholm T; McDonald JI; Kobyra J; Palmer E; Noonepalle S; Villagra A; Leitenberg D; Bollard CM; Saunthararajah Y; Chiappinelli KB
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36343976
[TBL] [Abstract][Full Text] [Related]
10. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
11. IP-score correlated to endogenous tumour antigen peptide processing: A candidate clinical response score algorithm of immune checkpoint inhibitors therapy in multiple cohorts.
Wang Y; Yan K; Guo Y; Lu Y; Su H; Li H
Front Immunol; 2022; 13():1085491. PubMed ID: 36700205
[TBL] [Abstract][Full Text] [Related]
12. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer.
Finn OJ
Ann Oncol; 2012 Sep; 23 Suppl 8(Suppl 8):viii6-9. PubMed ID: 22918931
[TBL] [Abstract][Full Text] [Related]
13. Fc Fragment of IgE Receptor Ig (FCER1G) acts as a key gene involved in cancer immune infiltration and tumour microenvironment.
Yang R; Chen Z; Liang L; Ao S; Zhang J; Chang Z; Wang Z; Zhou Y; Duan X; Deng T
Immunology; 2023 Feb; 168(2):302-319. PubMed ID: 36054819
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapy in immune-oncology.
Jones PA; Ohtani H; Chakravarthy A; De Carvalho DD
Nat Rev Cancer; 2019 Mar; 19(3):151-161. PubMed ID: 30723290
[TBL] [Abstract][Full Text] [Related]
15. Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC).
Cao R; Yuan L; Ma B; Wang G; Tian Y
Cancer Immunol Immunother; 2021 Jan; 70(1):1-18. PubMed ID: 32617668
[TBL] [Abstract][Full Text] [Related]
16. m
Cao X; Geng Q; Fan D; Wang Q; Wang X; Zhang M; Zhao L; Jiao Y; Deng T; Liu H; Zhou J; Jia L; Xiao C
Mol Cancer; 2023 Mar; 22(1):42. PubMed ID: 36859310
[TBL] [Abstract][Full Text] [Related]
17. Reshaping immunometabolism in the tumour microenvironment to improve cancer immunotherapy.
Chen S; Duan H; Sun G
Biomed Pharmacother; 2023 Aug; 164():114963. PubMed ID: 37269814
[TBL] [Abstract][Full Text] [Related]
18. Regulation of epigenetic modifications in the head and neck tumour microenvironment.
Liu H; Wang D; Yang Z; Li S; Wu H; Xiang J; Kan S; Hao M; Liu W
Front Immunol; 2022; 13():1050982. PubMed ID: 36405713
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of transposable elements is associated with immune evasion and poor outcome in colorectal cancer.
Zhu X; Fang H; Gladysz K; Barbour JA; Wong JWH
Eur J Cancer; 2021 Nov; 157():94-107. PubMed ID: 34492588
[TBL] [Abstract][Full Text] [Related]
20. DNA hypomethylation mediates immune response in pan-cancer.
Zhang C; Sheng Q; Zhao N; Huang S; Zhao Y
Epigenetics; 2023 Dec; 18(1):2192894. PubMed ID: 36945884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
